NCT00535145 - Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

SchizophreniaSchizoaffective DisorderPsychotic Disorders

Interventions

DRUG

Treatment as usual (TAU), Paliperidone ER

Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks

Trial Locations (21)

Unknown

Cerritos

Chino

Garden Grove

Huntington Beach

Santa Ana

Torrance

Fort Lauderdale

Hollywood

Kissimmee

Lake Charles

Flowood

Kansas City

Clementon

Albuquerque

Staten Island

Cincinnati

Norristown

Philadelphia

Sioux Falls

Irving

White River Junction

All Listed Sponsors

lead

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY